Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The analysis of vitamin D levels included six studies (15, 16, 22 to 24) and revealed no statistically significant differences between GD patients and controls (SMD = 0.38, 95% CI [-1.21, 1.96], P > 0.05).

Source: Vitamin D and serum calcium analysis. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Review / evidence synthesis.

Review / evidence synthesis

Reviews existing research; the exact review methods need further assessment.

Meta-analysis reported · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Graves’ disease and bone mineral density: a meta-analysis and UK Biobank

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Graves’ disease and bone mineral density: a meta-analysis and UK Biobank

Review / evidence synthesis · Frontiers in Endocrinology · 2026

Original publication title

Graves’ disease and bone mineral density: a meta-analysis and UK Biobank

Mengchu Wu; Jie Wang; Yunlin Lu; Mengting Yuan; Jiangxun Ji; Junhao Liang; Jiarui Cui; Hongyu Wang; Hongbin Xu; Tianpeng Liu; Yi Shen; Furui Fu; Senjie Shi; Qi Shi; Libing Shen; Dezhi Tang; Chunchun Yuan; Yongjun Wang

Copyright © 2026 Wu, Wang, Lu, Yuan, Ji, Liang, Cui, Wang, Xu, Liu, Shen, Fu, Shi, Shi, Shen, Tang, Yuan and Wang.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

This dual-evidence approach provides suggestive, rather than definitive, evidence that GD is associated with reduced BMD. The meta-analysis suggested widespread BMD reductions in GD patients. However, due to the limited number of confirmed GD cases, the fully adjusted UK Biobank analysis adopted a broader exposure definition of hyperthyroidism and observed a nominally statistically significant association only at the ribs, with no significant differences detected at other skeletal sites. Given the limited replication of the meta-analysis findings and the high heterogeneity observed in the meta-analysis, we advocate for a risk-stratified approach to BMD screening that prioritizes postmenopausal women, older adults, and individuals with low BMI, rather than routine screening for all GD patients.

These findings underscore the need for prospective studies with standardized protocols to clarify the skeletal impact of GD and to guide evidence-based bone health management.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To investigate the association between Graves’ disease (GD) and bone mineral density by integrating a meta-analysis with a large-scale cross-sectional analysis in the UK Biobank.

Source: Objective

Abstract: What methods does the paper describe?

We systematically searched PubMed, Web of Science, and Cochrane Library for cohort and cross-sectional studies. The pooled findings were then examined in the UK Biobank using multivariable linear regression models with adjustment for age, BMI, lifestyle factors, vitamin D, calcium, and sex.

Source: Methods

Abstract: Results

The meta-analysis (14 studies, 3,643 participants) showed that GD patients had significantly lower bone mineral density than controls (Mean Difference = −0.09, 95% CI [−0.10, −0.07], P < 0.001) and higher serum calcium (Standard Mean Difference = 0.37, 95% CI [0.18, 0.57], P = 0.023). However, substantial between-study heterogeneity was observed (I2 = 92.1%), indicating considerable variation across studies. Meta-regression and subgroup analyses identified postmenopausal women, older age (>50 years), and lower BMI as key factors amplifying the association.

In the UK Biobank (n = 42374), after rigorous adjustment for all covariates, the association was substantially attenuated and remained statistically significant only at the ribs (P < 0.05), while other skeletal sites, including the lumbar spine and femoral neck, showed no significant differences.

Source: Results

Abstract: Conclusion

This dual-evidence approach provides suggestive, rather than definitive, evidence that GD is associated with reduced BMD. The meta-analysis suggested widespread BMD reductions in GD patients. However, due to the limited number of confirmed GD cases, the fully adjusted UK Biobank analysis adopted a broader exposure definition of hyperthyroidism and observed a nominally statistically significant association only at the ribs, with no significant differences detected at other skeletal sites. Given the limited replication of the meta-analysis findings and the high heterogeneity observed in the meta-analysis, we advocate for a risk-stratified approach to BMD screening that prioritizes postmenopausal women, older adults, and individuals with low BMI, rather than routine screening for all GD patients.

These findings underscore the need for prospective studies with standardized protocols to clarify the skeletal impact of GD and to guide evidence-based bone health management.

Source: Conclusion
Authors’ abstract

Objective

To investigate the association between Graves’ disease (GD) and bone mineral density by integrating a meta-analysis with a large-scale cross-sectional analysis in the UK Biobank.

Methods

We systematically searched PubMed, Web of Science, and Cochrane Library for cohort and cross-sectional studies. The pooled findings were then examined in the UK Biobank using multivariable linear regression models with adjustment for age, BMI, lifestyle factors, vitamin D, calcium, and sex.

Results

The meta-analysis (14 studies, 3,643 participants) showed that GD patients had significantly lower bone mineral density than controls (Mean Difference = −0.09, 95% CI [−0.10, −0.07], P < 0.001) and higher serum calcium (Standard Mean Difference = 0.37, 95% CI [0.18, 0.57], P = 0.023). However, substantial between-study heterogeneity was observed (I2 = 92.1%), indicating considerable variation across studies. Meta-regression and subgroup analyses identified postmenopausal women, older age (>50 years), and lower BMI as key factors amplifying the association.

In the UK Biobank (n = 42374), after rigorous adjustment for all covariates, the association was substantially attenuated and remained statistically significant only at the ribs (P < 0.05), while other skeletal sites, including the lumbar spine and femoral neck, showed no significant differences.

Conclusion

This dual-evidence approach provides suggestive, rather than definitive, evidence that GD is associated with reduced BMD. The meta-analysis suggested widespread BMD reductions in GD patients. However, due to the limited number of confirmed GD cases, the fully adjusted UK Biobank analysis adopted a broader exposure definition of hyperthyroidism and observed a nominally statistically significant association only at the ribs, with no significant differences detected at other skeletal sites. Given the limited replication of the meta-analysis findings and the high heterogeneity observed in the meta-analysis, we advocate for a risk-stratified approach to BMD screening that prioritizes postmenopausal women, older adults, and individuals with low BMI, rather than routine screening for all GD patients.

These findings underscore the need for prospective studies with standardized protocols to clarify the skeletal impact of GD and to guide evidence-based bone health management.

Publication and source details

Original title: Graves’ disease and bone mineral density: a meta-analysis and UK Biobank

Mengchu Wu; Jie Wang; Yunlin Lu; Mengting Yuan; Jiangxun Ji; Junhao Liang; Jiarui Cui; Hongyu Wang; Hongbin Xu; Tianpeng Liu; Yi Shen; Furui Fu; Senjie Shi; Qi Shi; Libing Shen; Dezhi Tang; Chunchun Yuan; Yongjun Wang

Frontiers in Endocrinology · 2026

* Correspondence: Yongjun Wang, wangyongjun@shutcm.edu.cn; Chunchun Yuan, ccyuan0831@shutcm.edu.cn; Dezhi Tang, dztang@shutcm.edu.cn; Libing Shen, steveshen79@gmail.com

†These authors have contributed equally to this work and share first authorship

Copyright © 2026 Wu, Wang, Lu, Yuan, Ji, Liang, Cui, Wang, Xu, Liu, Shen, Fu, Shi, Shi, Shen, Tang, Yuan and Wang.2026Wu, Wang, Lu, Yuan, Ji, Liang, Cui, Wang, Xu, Liu, Shen, Fu, Shi, Shi, Shen, Tang, Yuan and Wanghttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declared that financial support was received for this work and/or its publication. This study was supported by the Innovative Drug Research and Development National Science and Technology Major Project (2025ZD1801400, 2025ZD1801401), the Key Program of the National Natural Science Foundation of China (82530121), National Natural Science Foundation of China (NSFC) (82274548, 82505624), Inheritance and Innovation Team Project of National Traditional Chinese Medicine (ZYYCXTD-C-202202), Shanghai Sailing Program (24YF2746300), China Association of Chinese Medicine (CACM) FY2024 Clinical Research Program on Osteoporosis-Targeted Proprietary Chinese Medicines (GA_CACM_2024002), the Third Round of Honorary System (Distinguished Professor) Position Program at Shanghai University of Traditional Chinese Medicine (Shangzhongyi Renzi [2024] 54 No. 12), Shanghai Universities Distinguished Professor (Eastern Scholar) Position Program (TP2022082).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T21:51:22.549535+00:00

DOI: 10.3389/fendo.2026.1794055 · PMC13541481